Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (3605)	4/27/2001 12:08:41 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

<<If it's good it will be a big deal as you note, because I don't think it's in many people's models even though PII is already planned.>> If it's good... It is PIb (safety) trail in healthy volunteers. I think it is two weeks dosing at lower-to-mid doses. It will not say anything about is it good or not? Plasma cytokine level may be effected, but it does not mean that will last or will have beneficial effects. Even VRTX PIIa trial for VX-745 or VX-740-ICE (four weeks) is not confirmation of the target or compound, so hope investors (and surely SCIO) may not overdue in hype. Miljenko